SuperworthZymeworks revenue ZYME
Sales by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- $37.1M
- Latest quarter, Q2 FY26
- $4.6M
- −91% on a year earlier
- Fiscal year 2025
- $106M
- +39% on the year before
Zymeworks' revenue was $37.1M over the twelve months to Jun 30, 2026, down 70% on a year earlier.
In its latest quarter, Q2 FY26, it was $4.6M, down 91% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $106M | +39% |
| FY2024 | $76.3M | +0% |
| FY2023 | $76M | −82% |
| FY2022 | $412.5M | n/a |
| FY2021 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $4.6M | −91% | $37.1M | |
| Q1 FY26 | $2.4M | −91% | $81.3M | |
| Q4 FY25 | $2.5M | −92% | $106M | |
| Q3 FY25 | $27.6M | +73% | $134.5M | |
| Q2 FY25 | $48.7M | +153% | $122.9M | |
| Q1 FY25 | $27.1M | +170% | $93.4M | |
| Q4 FY24 | $31M | +83% | $76.3M | |
| Q3 FY24 | $16M | −3% | $62.2M | |
| Q2 FY24 | $19.2M | +175% | $62.7M | |
| Q1 FY24 | $10M | −72% | $50.5M | |
| Q4 FY23 | $16.9M | −96% | $76M | |
| Q3 FY23 | $16.5M | +527% | $461.6M |
Against its peers
Companies in Drug Manufacturers - General nearest Zymeworks' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| ZYMEZymeworks | $37.1M | −70% a year |
| HRMYHarmony Biosciences | $959.9M | +24% a year |
| PBHPrestige Consumer Healthcare | $1.1B | −1% a year |
| ANIPANI Pharmaceuticals | $978.4M | +31% a year |
| PAHCPhibro Animal Health | $1.5B | +17% a year |
| ANABAnaptysbio | n/m | |
| PCRXPacira BioSciences | $746.2M | +6% a year |
| NRIXNurix Therapeutics | $701.9M | |
| OMEROmeros | n/m | |
| OGNOrganon | $6.1B | −2% a year |
| AMPHAmphastar Pharmaceuticals | $730M | +1% a year |
| Peer median | $969.1M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Zymeworks
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.